Gold-standard test for latent tuberculosis infection will be covered by national health insurance Hilden, Germany, and Paris, France, June 22, 2017 – QIAGEN N.V. (NASDAQ: QGEN; Frankfurt Prime Standard: QIA) today announced that France’s Ministry of Health and Social Affairs has approved reimbursement by the national health insurance system for QIAGEN’s QuantiFERON-TB® Gold Plus (QFT-Plus®)... Read more
Fourth generation Latent TB blood test combines breakthrough CD4/CD8 design for comprehensive immune response detection with the most flexible blood collection workflow Germantown, Maryland, and Hilden, Germany, June 8, 2017 – QIAGEN N.V. (NASDAQ: QGEN; Frankfurt Prime Standard: QIA) today announced the U.S. regulatory approval of QuantiFERON®-TB Gold Plus (QFT®-Plus) the fourth generation of the market... Read more
High-throughput application of artus CMV QS-RGQ MDx Kit on QIAsymphony streamlines critical and frequently performed viral infection test for transplant patients Germantown, Maryland, and Hilden, Germany, June 6, 2017 – QIAGEN (NASDAQ: QGEN; Frankfurt Prime Standard: QIA) today announced it has received premarket approval from the U.S. Food and Drug Administration (FDA) for its automated... Read more
NEW YORK and HILDEN, Germany, (June 3, 2017) – Bristol-Myers Squibb Company (NYSE: BMY) and QIAGEN(NASDAQ: QGEN; Frankfurt Prime Standard: QIA) have signed an agreement to explore the use of next-generation sequencing (NGS) technology to develop gene expression profiles (GEPs) as predictive or prognostic tools for use with Bristol-Myers Squibb novel immuno-oncology (I-O) therapies in... Read more
Option to add new biomarkers for microsatellite instability (MSI) and mismatch repair (MMR) to QIAGEN’ s NGS panels Hilden, Germany, and Germantown, Maryland, June 3, 2017 – QIAGEN (NASDAQ: QGEN; Frankfurt Prime Standard: QIA) today announced it has received a worldwide license from The Johns Hopkins University for biomarkers that have been shown to play... Read more
VENLO, Niederlande, February 2, 2016 /PRNewswire/ — QIAGEN N.V. (NASDAQ: QGEN; Frankfurt Prime Standard: QIA) gab heute die Ergebnisse der operativen Tätigkeit für das vierte Quartal und für das Gesamtjahr 2015 bekannt. Das Unternehmen hat auf Basis konstanter Wechselkurse (CER) den bereinigten Konzernumsatz und Gewinn gesteigert. Gleichzeitig hat QIAGEN Ziele für die Beschleunigung von Wachstum... Read more
HILDEN, Deutschland und AARHUS, Dänemark, February 2, 2016 /PRNewswire/ — Zentren und Wissenschaftler der FDA erhalten Zugang zu QIAGENs umfangreichen Lösungen für Anwendungen in der mikrobiellen und metagenomischen Analyse sowie anderen Bereichen QIAGEN N.V. (NASDAQ: QGEN; Frankfurt Prime Standard: QIA) hat heute bekannt gegeben, dass das Unternehmen neue Partnerschaften eingegangen ist, um das Profil seiner... Read more
Partnership with a leading Chinese IVD company with goal to accelerate penetration of the world’s first complete Sample to Insight NGS solution in rapidly growing Chinese market Hilden, Germany, and Chengdu, China, May 2, 2017 – QIAGEN N.V. (NASDAQ: QGEN; Frankfurt Prime Standard: QIA) today announced the formation of a joint venture with Maccura Biotechnology... Read more
VENLO, The Netherlands, February 2, 2016 /PRNewswire/ — QIAGEN N.V. (NASDAQ: QGEN; Frankfurt Prime Standard: QIA) announced results of operations for the fourth quarter and full-year 2015, delivering higher adjusted net sales and earnings at constant exchange rates (CER) while setting goals for accelerating growth and further innovation in 2016. “QIAGEN made significant progress in... Read more
VENLO, The Netherlands, November 13 /PRNewswire-FirstCall/ -- - Worldwide First Solution for Flexible siRNA Selection Provides New Dimension of Utility and Performance in one of Life Sciences' Most Promising Disciplines QIAGEN, (Nasdaq: QGEN; Frankfurt, Prime Standard: QIA) the world's leading provider of products for pre-analytical sample preparation and a leader in molecular diagnostics, has introduced... Read more